LABELS · 17306ca2-c631-4281-824c-1cb6d63dcac1

CORTEF

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-02-17
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

INDICATIONS AND USAGE CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

Full extracted label fields

application numbers

NDA008697

boxed warning exact

brand names

CORTEF

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9ce19944-dd88-4a7b-84ca-b07f4ec23bad

generic names

HYDROCORTISONE

17306ca2-c631-4281-824c-1cb6d63dcac1

indications and usage exact

INDICATIONS AND USAGE CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

indications and usage tables exact

is original packager

true

manufacturer names

Pharmacia & Upjohn Company LLC

matched search terms

cancer
lymphomas
leukemia

package ndcs

0009-0012-01
0009-0031-01
0009-0044-01

product ndcs

0009-0012
0009-0031
0009-0044

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

197782
197783
197787
208680
208712
208816

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA008697

brand names

CORTEF

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 282
end exclusive: true
exact text: INDICATIONS AND USAGE CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where appl
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 0

current approval status

not_reconciled

duplicate text group

dup-575618d6bd7a99d959fe

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-bfb43f4b98f2076b44be

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

end: 50
end exclusive: true
exact text: are indicated
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 37

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 82
end exclusive: true
exact text: INDICATIONS AND USAGE CORTEF Tablets are indicated in the following conditions. 1.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 662
end exclusive: true
exact text: INDICATIONS AND USAGE CORTEF Tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rh
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 0

current approval status

not_reconciled

duplicate text group

dup-8d1aac8c2aaa4d7a63bb

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-f803775b899f24bf7d1b

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 462
end exclusive: true
exact text: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 83

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1118
end exclusive: true
exact text: rticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 263

current approval status

not_reconciled

duplicate text group

dup-6a76e9f56d8231da9e5e

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-18b6d36177f095389912

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 918
end exclusive: true
exact text: Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 463

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1304
end exclusive: true
exact text: aintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic derm
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 719

current approval status

not_reconciled

duplicate text group

dup-08e1cb7b6260c31c5e09

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-516675af7428f2c3264f

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1104
end exclusive: true
exact text: Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 919

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1513
end exclusive: true
exact text: condylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asth
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 905

current approval status

not_reconciled

duplicate text group

dup-e18ba4e9c3c0f7d7dcad

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-200271709c36b18e79aa

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1313
end exclusive: true
exact text: Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 1105

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1787
end exclusive: true
exact text: gic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zo
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 1114

current approval status

not_reconciled

duplicate text group

dup-c39c3884c85e14887201

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-800bffabab41d05fd531

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1587
end exclusive: true
exact text: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 1314

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2158
end exclusive: true
exact text: tractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate a
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 1388

current approval status

not_reconciled

duplicate text group

dup-8842ab908785d80c6536

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-3882bcf3810a6762f471

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1958
end exclusive: true
exact text: Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 1588

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2411
end exclusive: true
exact text: al marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid)
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 1759

current approval status

not_reconciled

duplicate text group

dup-48ec84fc66ea34ddde8f

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-20807a95512054b90489

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2211
end exclusive: true
exact text: Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 1959

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2632
end exclusive: true
exact text: 's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2012

current approval status

not_reconciled

duplicate text group

dup-9366fddc944f074d348e

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-df7c8a151fc6fbf151a2

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

context exact
ematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune)
kind
age
polarity
not_inferred
span
end
2279
end exclusive
true
exact text
adults
label id
17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start
2273
context exact
bocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (
kind
age
polarity
not_inferred
span
end
2316
end exclusive
true
exact text
adults
label id
17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start
2310

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2432
end exclusive: true
exact text: Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2212

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2748
end exclusive: true
exact text: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases T
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2233

current approval status

not_reconciled

duplicate text group

dup-ecff0c25a1a9519ffdb5

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-74366cb7c29fc8ac8d93

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

context exact
es For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.
kind
age
polarity
not_inferred
span
end
2516
end exclusive
true
exact text
adults
label id
17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start
2510

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2548
end exclusive: true
exact text: Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2433

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 11 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2920
end exclusive: true
exact text: anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impen
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2349

current approval status

not_reconciled

duplicate text group

dup-1312bdc8616ae518d6fa

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-2f3089444f4b5dc32584

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2720
end exclusive: true
exact text: Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2549

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 12 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3050
end exclusive: true
exact text: e leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvem
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2521

current approval status

not_reconciled

duplicate text group

dup-8dcf39128bee443e7467

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-c24ce9deeb3732dc5d60

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 2850
end exclusive: true
exact text: Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2721

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · unclassified context

application numbers

NDA008697

brand names

CORTEF

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 3053
end exclusive: true
exact text: remia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2651

current approval status

not_reconciled

duplicate text group

dup-cdba487c4e23451910c3

extraction review status

automated_candidate_pending_source_review

generic names

HYDROCORTISONE

ind-span-81a72573e7d8305a47b5

label id

17306ca2-c631-4281-824c-1cb6d63dcac1

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 3053
end exclusive: true
exact text: Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement
label id: 17306ca2-c631-4281-824c-1cb6d63dcac1
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 61b11221ccda7c87ba17c0df68f09737251f1881d698b0598963aed38474ce8f
start: 2851

source url

https://api.fda.gov/drug/label.json?search=id%3A%2217306ca2-c631-4281-824c-1cb6d63dcac1%22

spl effective date

2025-02-17

spl set id

9ce19944-dd88-4a7b-84ca-b07f4ec23bad

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Preserved source evidence · Not medical advice